Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 11/20 | 0.69 |
| ▸ | MAOA | P21397 | 10/20 | 0.69 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | GRM5 | P41594 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562544 | 0.93 | TOP1 (0.67) | TOP1MAOBMAOAGSTP1ALOX5 | |
| SCHEMBL9627742 | 0.85 | TOP1 (0.57) | TOP1MAOBMAOAGSTP1ALOX5 | |
| SCHEMBL9627734 | 0.84 | TOP1 (0.56) | TOP1MAOBMAOAGSTP1ALOX5 | |
| SCHEMBL316203 | 0.83 | MAOB (0.69) | TOP1MAOBMAOAGSTP1ALOX5 | |
| SCHEMBL9628330 | 0.82 | TOP1 (0.65) | TOP1MAOBMAOAGSTP1ALOX5 | |
| SCHEMBL7379163 | 0.81 | MAOA (1.00) | TOP1MAOBMAOAGSTP1ALOX5 | |
| SCHEMBL3759785 | 0.81 | MAOB (0.74) | TOP1MAOBMAOAGSTP1NPC1 | |
| SCHEMBL2601920 | 0.81 | NPC1 (0.56) | TOP1MAOBMAOAGSTP1NPC1 | |
| SCHEMBL2601928 | 0.79 | ALOX5 (0.58) | TOP1MAOBMAOAALOX5NPC1 | |
| SCHEMBL327001 | 0.79 | MAOB (0.84) | MAOBMAOANPC1GRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | TOP1 586/4885MAOB 3079/4885MAOA 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.